|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMATOPOIESIS
From the Hematopoiesis Department, American Red
Cross Holland Laboratory, Rockville, MD; the Research Institute
of Molecular Pathology, Vienna, Austria; the Division of Experimental
Hematology and the Biochemistry Department, St Jude Children's
Research Hospital, Memphis, TN; and the Howard Hughes Medical
Institute, Chevy Chase, MD.
Signal transducers and activators of transcription (STATs) are
intracellular mediators of cytokine receptor signals. Because many
early-acting growth factors have been implicated in STAT5 activation,
this study sought to investigate whether STAT5 may be a transcriptional
regulator of hematopoietic stem cell (HSC) long-term repopulating
activity. To test this possibility, bone marrow (BM) and fetal liver
(FL) cells from mice containing homozygous deletions of both STAT5a and
STAT5b genes (STAT5ab The functional roles of janus kinases (JAKs) and
signal transducers and activators of transcription (STATs) have been
characterized in both hematopoietic and nonhematopoietic
tissues.1 The JAK/STAT signaling axis allows a diverse set
of extracellular signals to result in modification of gene expression
patterns in the appropriate target cells. This process is initiated
when, on cytokine binding, JAKs come into close proximity and become
activated by autophosphorylation on tyrosine residues. Activated JAKs
then phosphoryate among many other substrates, the STAT proteins. STATs
form homodimers or heterodimers via SH2 domain phosphotyrosine
interactions and translocate to the nucleus where they bind to
transcriptional elements on DNA.2,3 Activated STAT
proteins regulate their target genes often with tissue specificity. In
the hematopoietic system, JAK/STAT signaling has been extensively
described in a variety of lymphoid and myeloid cell types. Four
mammalian JAKs and 7 STAT proteins have been identified and
characterized by generation of knockout mice.4 These
studies have revealed a large diversity in the role of STATs in
hematopoiesis with some STATs showing phenotypes primarily in
restricted cytokine pathways (eg, interferons, interleukin [IL]-4,
IL-12, and IL-13) that are primarily involved in immune responses
(STAT1, STAT2, STAT4, and STAT6). In contrast, the complex phenotypes
of STAT3- and STAT5-deficient mice demonstrate a broad cytokine
activation and function profile for many individual cell lineages.
STAT5a and STAT5b are 2 very homologous transcription factors with
variability between these 2 proteins being primarily in the
transactivation domain. Mice deficient in either STAT5a or STAT5b have
been generated and characterized. The STAT5a knockout mouse is
characterized by defects in responses to granulocyte-macrophage colony-stimulating factor (GM-CSF)5 and mammary gland
development.6 The STAT5b knockout mouse is characterized
by defects in growth hormone signaling and expression of
male-characteristic liver gene expression patterns.7 To
study the effects of STAT5 on hematopoiesis and also to eliminate any
compensating function between the 2 STAT isoforms, homozygous mutant
mice lacking both STAT5a and STAT5b were generated. These female mice
were infertile, but heterozygous mice could breed normally and give
viable STAT5ab Many of the growth factors reported to activate STAT514-21
have been shown to provide a survival signal for primitive
hematopoietic cells during ex vivo culture. For example, IL-3, IL-6,
stem cell factor (SCF),22,23 Flt3 ligand,24
and thrombopoietin (TPO)25-28 have been shown to stimulate
primitive hematopoietic cells to proliferate ex vivo when present at
the optimal concentrations and combinations. Tyrosine phosphorylation
of STAT5 in megakaryocytes and platelets after TPO treatment has been
well characterized.29-32 Therefore, given the activity of
TPO on multipotential cells and the stem cell-repopulating defect in
mice lacking the receptor for TPO (c-mpl),33-36 we were
interested in studying the role of STAT5 in the stem cell compartment.
Furthermore, TPO is known to be synergistic with other early-acting
cytokines such as SCF and Flt3 ligand.27 For applications
such as ex vivo retroviral gene transfer using hematopoietic cytokines,
STAT5 activation may also be required for the synergistic effects of
growth factor stimulation. The requirement for STAT5 as a common
signaling intermediate in primitive levels of hematopoiesis had not
been previously studied. Therefore, we have tested the hypothesis that
a block in signal transduction pathways involving STAT5 could result in
decreased stem cell activity in hematopoietic cells from
STAT5ab Mice and genotyping
Mouse peripheral blood hematology
Bone marrow/fetal liver cell collection and spleen colony-forming unit assays Bone marrow (BM) was harvested from both hind limbs (tibias and femurs) of either STAT5ab / or littermate wild-type
mice. BM cells were flushed into phosphate-buffered saline containing
2% fetal bovine serum (Hyclone, Logan UT) and counted using a
hemacytometer. Embryonic day 14.5 fetuses were collected after the
pregnant females were humanely killed, and the liver cells were
removed with a pair of sterile microforceps, dispersed with a 21-gauge
needle, and resuspended in phosphate-buffered saline containing 2%
fetal bovine serum. A small fraction (1:20) of the fetal liver (FL)
cells was then used the same day for STAT5 genotyping by PCR as
described above. The total number of BM cells obtained from each mouse
was used for calculation of the absolute number of spleen
colony-forming units (CFU-Ss) in the BM based on the frequency. CFU-S
assays were performed by using BM cells pooled from either 2 wild-type
or STAT5ab/ mice. CFU-Ss were harvested 12 days after
injection of standard doses of 5 × 104 or
1 × 105 cells via the lateral tail vein into recipient
mice irradiated with 900 rads of gamma radiation 2 to 4 hours earlier
(137Cs source; Mark I-68A model irradiator, J. L. Shepherd and Associates, San Fernando, CA). Manual scoring of CFU-S
colonies was aided by the use of a StereoZoom 6 Plus dissecting
microscope (Leica Microsystems, Buffalo, NY). Preliminary
characterization of CFU-S numbers in STAT5ab/ mice was
performed with 1 × 104, 5 × 104,
1 × 105, and 1 × 106 cells to find the
linear range. The numbers of CFU-Ss per spleen for the data in Figure
1B ranged from 4 to 10 using the
1 × 105 cell dose. A dose dependence on colony formation
was observed for all 3 experiments.
Antibody/fluorescent dye staining and flow cytometry BM cells were flushed from both hind limbs of STAT5ab/ and wild-type mice. BM cells were stained with
a cocktail of antibodies to phycoerythrin (PE)-conjugated lineage
markers that included Ly-6G (Gr-1), CD11b (Mac-1), CD45R/B220, CD4
(L3T4), CD8 (Ly-2), NK1.1 (NKR-P1B and NKR-P1C), and Ter119/Ly-76. The
cells were also stained with antibodies to fluorescein isothiocyanate
(FITC)-conjugated Ly-6A/E (Sca-1) and biotin-conjugated CD117 (c-kit).
The biotinylated c-kit antibody was detected by using a secondary
streptavidin-PE Cy5 conjugate. FL cells were collected as described
above and were stained with the same lineage cocktail except that CD11b (Mac-1) was not included.37 All antibodies for these
studies were obtained from PharMingen (San Diego, CA). For flow
cytometric analysis, cells were stained with 5 µg/mL Hoechst 33342 as
previously reported38 before antibody staining on ice.
Cells were then analyzed by using a FACSVantage SE flow cytometer (BD
Biosciences, San Jose, CA) equipped with the Enterprise IIC laser,
providing both 488 nm and UV (351-364 nm) excitation. The primary beam
was tuned to 488 nm at 100 mW for light scatter triggering, and the second beam was tuned to UV at 30 mW for Hoechst 33342 excitation. Fluorescence emission from bound Hoechst 33342 dye was measured at 2 wavelengths, blue fluorescence emission detected with a 424/44 bandpass
filter and red fluorescence emission with a 675 longpass filter.
Separation of the 2 signals was achieved with a 640-nm longpass
dichroic filter. Linear signals from both red and blue fluorescence
channels were collected and used to produce typical histograms for
identification of side-population (SP) cells. Small debris was
excluded from the analysis by electronic gating of the forward versus
orthogonal light scatter data. The SP cell gate was defined according
to normal C57Bl/6 BM and was similar to that reported38,39
The PE-conjugated lineage antibodies described also including Thy1.2
antibody were used for staining peripheral blood leukocyte populations
in mice that received transplants. The percentage of Ly-5.2 donor
engraftment in Ly-5.1 recipient mice was quantitated by using a
FITC-conjugated CD45.2 (anti-Ly-5.2) antibody in combination with the
PE-conjugated lineage antibodies.
Competitive repopulation assays BM cells were freshly harvested from both hind limbs of STAT5ab/ and littermate wild type mice. FL cells were
freshly harvested from embryonic day 14.5 fetuses and were genotyped
the same day by PCR. Cells were then mixed thoroughly at either 1:1 or
4:1 donor equivalent ratios with HW80 or Ly-5.1 BM or FL cells
collected at the same time. The cell mixtures were then injected via
the lateral tail vein into lethally irradiated (1100 rads) recipient mice. The minimum cell dose injected was 1.5 to 2 × 106
cells for each competed BM graft and 3 to 5 × 105 cells
for each FL graft. The average mixing ratio was
4.7 × 106 wild-type BM cells versus
2.1 × 106 STAT5ab/ BM cells, because the
BM cellularity for the STAT5ab/ mice was reduced. For
FL experiments, the average competed cells for wild- type and
STAT5ab/ was not different because FL cellularity was
not reduced (see "Results" section). Beginning at 8 weeks after
transplantation, mice were bled from the retroorbital venous plexus.
Hemoglobin patterns were analyzed from packed peripheral red blood
cells by electrophoresis on cellulose acetate gels. To calculate the relative proportions of single and diffuse donor hemoglobin in peripheral blood from reconstituted mice,40 the hemoglobin
gels were digitized by using a ScanJet IIcx/T scanner (Hewlett Packard, Palo Alto, CA). Data files were quantitated by densitometry using ImageQuant software (Molecular Dynamics). For experiments in which donor grafts were competed by using the Ly-5.1/Ly-5.2 system, mice were
analyzed by flow cytometry as described above.
Secondary BM transplantations BM was harvested from primary recipients at times up to 6 months after transplantation and injected via the lateral tail vein into lethally irradiated secondary recipients (1100 rads). Secondary transplanted mice received at least 5 × 106 BM cells each. Hemoglobin electrophoresis patterns were monitored in secondary recipients after reconstitution (4 months). For some analyses, the recipient mice were Ly-5.1 and engraftment was determined by FACS.Southern blot analyses Genomic DNA was prepared from peripheral blood, BM, and spleen cells from mice that received transplants by digestion with 0.6 mg/mL proteinase K in 50 mM Tris pH 8.0, 1% sodium dodecyl sulfate, 100 mM NaCl, and 10 mM EDTA pH 8.0. DNA was then extracted with an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) and precipitated with 2.5 volumes ice-cold ethanol and one-tenth volume sodium acetate. DNA (5-10 µg) was digested overnight with EcoRI and separated on a 0.8% agarose gel by electrophoresis. Gels were blotted overnight onto Hybond N+ nylon membrane (Amersham, Arlington Heights, IL), UV cross-linked, and hybridized with a [32P]-labeled fragment of the mouse -globin
intervening sequence 2. Blots were washed at a final stringency of
0.5 × SSC/0.5% sodium dodecyl sulfate at 65°C and exposed
overnight, and autoradiographic images were obtained by using a
Molecular Dynamics Storm phosphorimager and x-ray film (Eastman Kodak,
Rochester, NY). [32P]-(deoxycytidine triphosphate) dCTP
was obtained from Amersham.
STAT5ab mice 8 generations onto the C57Bl/6 background.
Heterozygote mice were then crossed to yield homozygous double-
knockout mice for analysis. The survival of homozygous mutant mice on
the C57Bl/6 background was very low, with 4-week survival of
approximately 5% of all mice genotyped. We have used the C57Bl/6
STAT5ab/ mice to further characterize the hematopoietic
defects relative to normal littermate wild-type mice and to determine
whether reduced long-term repopulating activity results from loss of
STAT5. The peripheral blood hematology of the backcrossed mice is shown
in Table 1. The peripheral white blood
cell counts were decreased because of a reduced percentage of
lymphocytes, and the hematocrits were near normal, except in aged mice
(> 3 months old) that developed splenomegaly and were not analyzed. A
mild increase in the absolute neutrophil count and absolute monocyte
count was also noted. This result is similar to our previous
observations in JAK3/ mice, suggesting a compensatory
mechanism for a decreased absolute lymphocyte count. Not shown in Table
1, we also determined the absolute red blood cell and platelet counts
by using the hematology analyzer for mice that did not receive
transplants. The red blood cell numbers were 67% of normal in the
STAT5ab/ mice (wild type
[8.2 ± 1.0 × 106/µL] versus
STAT5ab/ [5.5 ± 0.8 × 106/µL]
n = 6, P = .004). The platelet numbers were 40% of
normal in the STAT5ab/ mice (wild type
[1288 ± 271 × 103/µL] versus
STAT5ab/ [516 ± 107 × 103/µL] n = 6, P < .001).
For our studies, BM was collected from young mice (4-6 weeks) to avoid
age-related disease and death. Note that, because of the young age of
these mice, the BM cellularity from the wild type mice was slightly
lower than that typical of older mice. BM was harvested from both hind
limbs and, relative to littermate wild type mice,
STAT5ab STAT5ab (KLS)
(Figure 2A). The absolute number of these
cells was not different between wild-type and STAT5ab/
mice in either the BM or FL. The absolute number of KLS cells in the FL
(7218 ± 2234, n = 4) relative to normal littermate FL (9746 ± 2407, n = 5) was unchanged (P = .15).
Accordingly, the percentage of FL KLS cells (wild type
[0.25 ± 0.05%, n = 5] versus STAT5ab/
[0.24 ± 0.07%, n = 4]) and the FL cellularity (wild type
[2.1 ± 0.74 × 106, n = 11] versus
STAT5ab/ [2.1 ± 0.75 × 106,
n = 9]) did not differ between wild-type and
STAT5ab/ mice (P = .81 and 1.0, respectively). The adult BM from these mice also showed a normal
absolute number of KLS cells despite a reduction in total BM
cellularity (Figure 1). The absolute number of hind limb KLS cells was
quantitated at 23 010 ± 19 950 in STAT5ab/ mice
(n = 5) relative to 16 754 ± 12 566 for wild type mice
(n = 6), which was not significantly different
(P = .54). For the FL samples, a second method was used
that was based on Hoechst 33342 dye efflux (Figure 2B). The SP cells
reported after dual-emission wavelength analysis has been shown to be
enriched for repopulating cells, but they also contain lineage-positive
cells such as natural killer cells and erythroid progenitors
(Ter119+).41,42 We found that 60% to 70% of
BM KLS cells fall within the SP cell gate; therefore, significant
overlap occurs between these 2 parameters. The
c-kit+lin SP and
Sca-1+lin SP cell populations were
quantitated from both wild-type and STAT5ab/ FL cells.
No significant difference between wild-type and
STAT5ab/ FL SP cell percentage was found by using
either positive selection for c-kit or Sca-1. The
c-kit+lin SP number was 15 120 ± 4366 in
wild-type mice (n = 4) and 17 640 ± 8250 in
STAT5ab/ mice (n = 4), which was not significant
(P = .61). The Sca-1+lin SP
number was much lower and included only 420 ± 148 cells in wild-type
mice (n = 5) and 210 ± 75 cells in STAT5ab/ mice
(n = 4, but the difference between wild-type and
STAT5ab/ mice was significant (P = .04).
However, because the Sca-1+lin SP fraction
was much lower than the c-kit+lin SP
fraction, the total numbers of STAT5ab/ SP cells were
not reduced.
Further studies demonstrated that reconstitution of hematopoiesis could
be achieved after direct transplantation of 5 × 106
STAT5ab
BM from STAT5ab / mice with those from littermate wild-type mice
to determine whether differences in relative stem cell activity were
evident. For these experiments, BM cells were harvested from either
STAT5ab/ or littermate wild-type mice (C57Bl/6
background; Hbs) and competed at a 1:1 ratio with cells
from HW80 mice (Hbd). Mixing based on ratio was important
because total BM cellularity does not necessarily correlate with
absolute stem cell content. Beginning as early as 7 weeks after
transplantation and continued monthly until 6 months before
transplantation, mice from BM competitive repopulation experiment no. 1 were analyzed for the relative levels of donor engraftment (Figure
5A). The Hbs band was always
absent even at the earliest time points for the
STAT5ab/ grafts in all experiments. BM from wild-type
mice (nos. 8-10) competed effectively with the competitor marrow,
resulting in mice with the expected chimerism (38% ± 6%). In
contrast, BM from STAT5ab/ mice was completely
outcompeted by the competitor marrow, indicating a greatly reduced
long-term repopulating activity (mice nos. 1-7). At the time the mice
from the competitive repopulation experiment (mice nos. 1, 2, 4, 9, and
10) were humanely killed, secondary transplanted mice were generated
and followed for 4 months to continue analysis (Figure 5B). The average
percentage of Hbs in 7 secondary transplanted mice was not
significantly changed from the average found in the primary
transplanted mice after wild-type competitive repopulation
(32% ± 10%, n = 7, P = .37). As in the primary
transplantation, no reconstitution was seen in secondary recipients
from the STAT5ab/ competitive repopulation. The defects
in secondary reconstitution rule out a phenotype restricted to
short-lived progenitors. Two additional competitive repopulation
experiments analyzed at 4 and 3 months after transplantation showed
identical results for the STAT5ab/ BM graft (experiment
no. 2, n = 5; experiment no. 3, n = 8) and the wild-type graft
(experiment no. 2, 54% ± 3%, n = 3; experiment no. 3, 56%,
n = 2). The average percentage of chimerism in the 1:1 mixed
wild-type grafts for the 3 separate experiments was 49% ± 10%.
To confirm the hemoglobin reconstitution analysis results by Southern
blot for the single and diffuse alleles, primary transplanted mice were
killed at 6 months, and genomic DNA was prepared from leukocytes
obtained from peripheral blood, BM, and spleen (SP) of mice nos. 2, 4, 9, and 10. For mouse no. 1 only peripheral blood was obtained for
analysis. Southern blot analysis of the DNA from mice in each
experimental group was then performed (Figure 6). The Southern blots were probed with a
fragment of the
FL cells harvested from STAT5ab / mice, we characterized a more
primitive stage of hematopoietic cell development in the competitive
repopulation assay. FL cells were mixed at 1:1 donor ratios, and,
because the FL cellularity was unchanged, the cell doses competed were
identical. When equal donor equivalents from pools of 2 wild-type or
STAT5ab/ FL were mixed with HW80 mouse FL cells, the
reconstitution from the STAT5ab/ graft was completely
outcompeted at all times measured up to 20 weeks after transplantation
(Figure 7A). This result was identical to
that obtained with adult BM, indicating that autoreactive T cells,
which are absent at this developmental stage, are not responsible for
the dysfunction in hematopoietic reconstitution on BM or FL transplantation. A second experiment was performed in the hemoglobin system with identical results (STAT5ab/ n = 5, wild
type n = 3, data not shown). A third experiment was also performed
using the CD45 marker after mixing of FL cells from 2 separate donor
mice with Ly-5.1 FL cells at either a 1:1 or 4:1 ratio. A
representative example of both wild-type and STAT5ab/
competitions is shown (Figure 7B) from a total of 5 recipients of 1:1
mixed cells and 3 recipients of 4:1 mixed cells for both the wild-type
and STAT5ab/ groups. This approach complements the
hemoglobin electrophoresis results and provides quantitative
multilineage characterization of the repopulating defects. We have
mixed STAT5ab/ (Ly-5.2) or wild-type E14.5 FL cells
harvested from the same pregnant female (Ly-5.2) at donor equivalent
ratios of 1:1 or 4:1 versus wild-type E14.5 FL cells from a Ly-5.1
pregnant female. Multilineage engraftment was determined by costaining
for Gr-1, Mac-1, B220, CD4, or Ter119 markers and for Ly-5.2 at 10 and
17 weeks after transplantation, with no changes observed between the 2 time points. Wild-type livers competed with values consistent with the
input 50% (28%-59% range) or 80% (61%-93% range) mixing ratio.
Even with the 4:1 mixing ratio, the STAT5ab/ graft only
contributed from undetectable to 3.7%. The levels of engraftment of
CD4+ T cells were always undetectable for the
STAT5ab/ graft and in rank order were B220+
B cells (1.3%-1.6%), Ter119+ erythroid progenitors
(1.6%-1.7%), Gr-1+ myeloid cells (3.3%-4.6%), and
Mac-1+ myeloid cells (3.7%-4.7%). The net overall
repopulating deficiency was thus greatest in T cells (because
undetectable) and could be quantitated at 25- to 28-fold for
granulocytes (Gr-1) and macrophage (Mac-1), 45-fold for erythroid
progenitors (Ter119), and 68-fold for B lymphocytes. This result
formally demonstrates the lymphomyeloid nature, the severity, and the
generalizability of the repopulating defect in hematopoietic cells from
STAT5ab/ mice.
Many of the growth factors that have characterized biologic
activities on primitive hematopoietic cells have been shown to induce
phosphorylation of STAT5 via the JAKs. Although this indirect evidence
suggested that STAT5 activation might be important for cytokine
stimulation of HSCs, no functional studies using STAT5-deficient mice
had been performed. In addition, other signal transduction pathways
apart from the JAK-STAT pathway could serve redundant functions, making
the role of JAKs and STATs in HSCs uncertain. For example, both TPO and
SCF can activate other downstream molecules such as SHC, Raf-1/MAP
kinase, and phosphatidylinositol-3' kinase43-49 in various
cell types. The requirement for any of these pathways in the HSC has
not been directly studied. To address the role of STAT5 signaling in
the earliest stages of hematopoietic differentiation, we have initiated
studies using a STAT5ab As previously reported, we found that STAT5ab We have hypothesized that STAT5 activation plays a significant role in
HSC function, in addition to its functions important for progenitor
cell proliferation. Competitive repopulation experiments presented here
revealed a marked decrease in the long-term repopulating activity of
STAT5ab Consistent with the results of our study, challenge with 80 mg/kg carboplatin and 750 rads Cs137 irradiation has revealed a markedly slower recovery of platelets, hemoglobin, and white blood cells (Carl W. Jackson and Tamari I. Pestina, St Jude Children's Research Hospital, personal communication, November 2, 2000) and a lower survival rate59 even when given a normally rescuing dose of pegylated recombinant murine megakaryocyte growth and development factor. In our study here we show that during conditions of stress, such as after BM transplantation, defects in STAT5 activation may be more easily observed than during steady-state hematopoiesis. Because our transplantation model using mutant BM and FL cells is one with perturbed hematopoiesis, the lack of correlation between KLS number and function is not unexpected. Studies in which the HSC phenotype fails to correlate with function60,61 have been described as well as the demonstration that CD34 expression can be reversibly modulated62 in HSCs. Practical limitations in the numbers of viable mice and KLS cells that could be obtained from the C57Bl/6 colony did not allow scale up to perform limiting dilution studies with sorted cells. Therefore, we cannot conclude whether the marked repopulating defect in the mutant mice is due to a reduced quality or to a reduced quantity of stem cells. The specific growth factors that are relevant for the reduced in vivo
reconstitution ability of STAT5ab In summary, we have demonstrated that STAT5 activity is essential for normal long-term repopulation of lethally irradiated hosts. Therefore, in addition to a role in progenitor cell function, STAT5 plays an important role in the earliest stages of differentiation from the lymphomyeloid repopulating HSCs. This finding has implications for BM transplantation, suggesting that use of STAT5-activating cytokines may be beneficial for promoting stable long-term engraftment.
We thank David Bodine (Genetics and Molecular Biology Branch,
Hematopoiesis Section, National Human Genome Research Institute, National Institutes of Health) for providing the murine
Submitted March 6, 2001; accepted September 7, 2001.
Supported by the American Lebanese Syrian Associated Charities, the Howard Hughes Medical Institute, and the American Red Cross.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Kevin D. Bunting, Hematopoiesis Dept, American Red Cross Holland Laboratory, 15601 Crabbs Branch Way, Rockville, MD; e-mail: buntingk{at}usa.redcross.org.
1. Ihle JN, Nosaka T, Thierfelder W, Quelle FW, Shimoda K. Jaks and Stats in cytokine signaling. Stem Cells. 1997;15(suppl 1):105-111.
2.
Darnell JEJ.
STATs and gene regulation.
Science.
1997;277:1630-1635 3. Ihle JN. STATs: signal transducers and activators of transcription. Cell. 1996;84:331-334[CrossRef][Medline] [Order article via Infotrieve]. 4. Akira S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells. 1999;17:138-146[Medline] [Order article via Infotrieve].
5.
Feldman GM, Rosenthal LA, Liu X, et al.
STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression.
Blood.
1997;90:1768-1776
6.
Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L.
Stat5a is mandatory for adult mammary gland development and lactogenesis.
Genes Dev.
1997;11:179-186
7.
Udy GB, Towers RP, Snell RG, et al.
Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression.
Proc Natl Acad Sci U S A.
1997;94:7239-7244 8. Moriggl R, Sexl V, Piekorz R, Topham D, Ihle JN. Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity. 1999;11:225-230[CrossRef][Medline] [Order article via Infotrieve]. 9. Moriggl R, Topham DJ, Teglund S, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 1999;10:249-259[CrossRef][Medline] [Order article via Infotrieve].
10.
Kieslinger M, Woldman I, Moriggl R, et al.
Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation.
Genes Dev.
2000;14:232-244
11.
Matsumoto A, Seki Y, Kubo M, et al.
Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice.
Mol Cell Biol.
1999;19:6396-6407 12. Teglund S, McKay C, Schuetz E, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998;93:841-850[CrossRef][Medline] [Order article via Infotrieve].
13.
Sexl V, Piekorz R, Moriggl R, et al.
Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of Stat5.
Blood.
2000;96:2277-2283 14. Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J. 1996;15:2425-2433[Medline] [Order article via Infotrieve]. 15. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631[CrossRef][Medline] [Order article via Infotrieve].
16.
Oda A, Sawada K, Druker BJ, et al.
Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and STAT5B in primary cultured human erythroid precursors.
Blood.
1998;92:443-451 17. Nagata Y, Todokoro K. Interleukin 3 activates not only JAK2 and STAT5, but also Tyk2, STAT1, and STAT3. Biochem Biophys Res Commun. 1996;221:785-789[CrossRef][Medline] [Order article via Infotrieve].
18.
Brizzi MF, Dentelli P, Rosso A, Yarden Y, Pegoraro L.
STAT protein recruitment and activation in c-Kit deletion mutants.
J Biol Chem.
1999;274:16965-16972 19. Ryan JJ, Huang H, McReynolds LJ, et al. Stem cell factor activates STAT-5 DNA binding in IL-3-derived bone marrow mast cells. Exp Hematol. 1997;25:357-362[Medline] [Order article via Infotrieve]. 20. Linnekin D, Mou S, Deberry CS, et al. Stem cell factor, the JAK-STAT pathway and signal transduction. Leuk Lymphoma. 1997;27:439-444[Medline] [Order article via Infotrieve]. 21. Piekorz RP, Nemetz C, Hocke GM. Members of the family of IL-6-type cytokines activate Stat5a in various cell types. Biochem Biophys Res Commun. 1997;236:438-443[CrossRef][Medline] [Order article via Infotrieve].
22.
Bodine DM, Karlsson S, Nienhuis AW.
Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells.
Proc Natl Acad Sci U S A.
1989;86:8897-8901
23.
Bodine DM, Orlic D, Birkett NC, Seidel NE, Zsebo KM.
Stem cell factor increases colony-forming unit-spleen number in vitro in synergy with interleukin-6, and in vivo in Sl/Sld mice as a single factor.
Blood.
1992;79:913-919
24.
Shah AJ, Smogorzewska EM, Hannum C, Crooks GM.
Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38
25.
Ku H, Yonemura Y, Kaushansky K, Ogawa M.
Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice.
Blood.
1996;87:4544-4551
26.
Sitnicka E, Lin N, Priestley GV, et al.
The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells.
Blood.
1996;87:4998-5005
27.
Ramsfjell V, Borge OJ, Veiby OP, et al.
Thrombopoietin, but not erythropoietin, directly stimulates multilineage growth of primitive murine bone marrow progenitor cells in synergy with early acting cytokines: distinct interactions with the ligands for c-kit and FLT3.
Blood.
1996;88:4481-4492 28. Murray LJ, Young JC, Osborne LJ, Luens KM, Scollay R, Hill BL. Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+ cells and recruit primitive CD34+ Thy-1+ cells into rapid division. Exp Hematol. 1999;27:1019-1028[CrossRef][Medline] [Order article via Infotrieve]. 29. Ooi J, Tojo A, Asano S, Sato Y, Oka Y. Thrombopoietin induces tyrosine phosphorylation of a common beta subunit of GM-CSF receptor and its association with Stat5 in TF-1/TPO cells. Biochem Biophys Res Commun. 1998;246:132-136[CrossRef][Medline] [Order article via Infotrieve]. 30. Bacon CM, Tortolani PJ, Shimosaka A, Rees RC, Longo DL, O'Shea JJ. Thrombopoietin (TPO) induces tyrosine phosphorylation and activation of STAT5 and STAT3. FEBS Lett. 1995;370:63-68[CrossRef][Medline] [Order article via Infotrieve]. 31. Pallard C, Gouilleux F, Benit L, et al. Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J. 1995;14:2847-2856[Medline] [Order article via Infotrieve].
32.
Drachman JG, Sabath DF, Fox NE, Kaushansky K.
Thrombopoietin signal transduction in purified murine megakaryocytes.
Blood.
1997;89:483-492
33.
Solar GP, Kerr WG, Zeigler FC, et al.
Role of c-mpl in early hematopoiesis.
Blood.
1998;92:4-10
34.
Kimura S, Roberts AW, Metcalf D, Alexander WS.
Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin.
Proc Natl Acad Sci U S A.
1998;95:1195-1200
35.
Carver-Moore K, Broxmeyer HE, Luoh SM, et al.
Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice.
Blood.
1996;88:803-808
36.
Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D.
Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl.
Blood.
1996;87:2162-2170
37.
Morrison SJ, Hemmati HD, Wandycz AM, Weissman IL.
The purification and characterization of fetal liver hematopoietic stem cells.
Proc Natl Acad Sci U S A.
1995;92:10302-10306
38.
Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC.
Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.
J Exp Med.
1996;183:1797-1806 39. Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 1997;3:1337-1345[CrossRef][Medline] [Order article via Infotrieve]. 40. Whitney JB. Simplified typing of mouse hemoglobin (Hbb) phenotypes using cystamine. Biochem Gen. 1978;16:667-672[CrossRef][Medline] [Order article via Infotrieve].
41.
Storms RW, Goodell MA, Fisher A, Mulligan RC, Smith C.
Hoechst dye efflux reveals a novel CD7(+)CD34( 42. Zhou S, Morris JJ, Bunting KD, et al. Expression of the breast cancer resistance protein (bcrp) in side population (sp) stem cells, natural killer (nk) lymphocytes, and erythroid progenitor cells [abstract]. Blood. 2000;96:820a.
43.
Gurney AL, Wong SC, Henzel WJ, de Sauvage FJ.
Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation.
Proc Natl Acad Sci U S A.
1995;92:5292-5296 44. Morita H, Tahara T, Matsumoto A, Kato T, Miyazaki H, Ohashi H. Functional analysis of the cytoplasmic domain of the human Mpl receptor for tyrosine-phosphorylation of the signaling molecules, proliferation and differentiation. FEBS Lett. 1996;395:228-234[CrossRef][Medline] [Order article via Infotrieve]. 45. Rouyez MC, Boucheron C, Gisselbrecht S, Dusanter-Fourt I, Porteu F. Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway. Mol Cell Biol. 1997;17:4991-5000[Abstract]. 46. Sasaki K, Odai H, Hanazono Y, et al. TPO/c-mpl ligand induces tyrosine phosphorylation of multiple cellular proteins including proto-oncogene products, Vav and c-Cbl, and Ras signaling molecules. Biochem Biophys Res Commun. 1995;216:338-347[CrossRef][Medline] [Order article via Infotrieve].
47.
O'Farrell AM, Ichihara M, Mui AL, Miyajima A.
Signaling pathways activated in a unique mast cell line where interleukin-3 supports survival and stem cell factor is required for a proliferative response.
Blood.
1996;87:3655-3668
48.
Blume-Jensen P, Ronnstrand L, Gout I, Waterfield MD, Heldin CH.
Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C.
J Biol Chem.
1994;269:21793-21802
49.
Zauli G, Bassini A, Vitale M, et al.
Thrombopoietin enhances the alpha IIb beta 3-dependent adhesion of megakaryocytic cells to fibrinogen or fibronectin through PI 3 kinase.
Blood.
1997;89:883-895
50.
Fujii H, Nakagawa Y, Schindler U, et al.
Activation of Stat5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission.
Proc Natl Acad Sci U S A.
1995;92:5482-5486 51. Mui AL, Wakao H, O'Farrell AM, Harada N, Miyajima A. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J. 1995;14:1166-1175[Medline] [Order article via Infotrieve]. 52. Azam M, Erdjument-Bromage H, Kreider BL, et al. Interleukin-3 signals through multiple isoforms of Stat5. EMBO J. 1995;14:1402-1411[Medline] [Order article via Infotrieve].
53.
Lischke A, Moriggl R, Brandlein S, et al.
The interleukin-4 receptor activates STAT5 by a mechanism that relies upon common gamma-chain.
J Biol Chem.
1998;273:31222-31229
54.
Nicholson SE, Starr R, Novak U, Hilton DJ, Layton JE.
Tyrosine residues in the granulocyte colony-stimulating factor (G-CSF) receptor mediate G-CSF-induced differentiation of murine myeloid leukemic (M1) cells.
J Biol Chem.
1996;271:26947-26953
55.
Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF.
Fetal anemia and apoptosis of red cell progenitors in Stat5a 56. Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell. 1997;91:661-672[CrossRef][Medline] [Order article via Infotrieve]. 57. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 2000;404:193-197[CrossRef][Medline] [Order article via Infotrieve]. 58. Nemetz C, Hocke GM. Transcription factor Stat5 is an early marker of differentiation of murine embryonic stem cells. Differentiation. 1998;62:213-220[CrossRef][Medline] [Order article via Infotrieve].
59.
Pestina TI, Hutson NK, Parganas E, Moriggl R, Ihle JN, Jackson CW.
The antiapoptotic function of megakaryocyte growth and development factor (PEG-rmMGDF) is disrupted in STAT5ab
60.
Spangrude GJ, Brooks DM, Tumas DB.
Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenotype but not function.
Blood.
1995;85:1006-1016
61.
de Haan G, Szilvassy SJ, Meyerrose TE, Dontje B, Grimes B, Van Zant G.
Distinct functional properties of highly purified hematopoietic stem cells from mouse strains differing in stem cell numbers.
Blood.
2000;96:1374-1379
62.
Sato T, Laver JH, Ogawa M.
Reversible expression of CD34 by murine hematopoietic stem cells.
Blood.
1999;94:2548-2554
63.
Zhang S, Fukuda S, Lee Y, et al.
Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling.
J Exp Med.
2000;192:719-728
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  C. R. Geest, M. Buitenhuis, E. Vellenga, and P. J. Coffer Ectopic expression of C/EBP{alpha} and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia Haematologica, August 1, 2009; 94(8): 1075 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Wang, G. Li, W. Tse, and K. D. Bunting Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement Blood, May 14, 2009; 113(20): 4856 - 4865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ohmori, Y. Luo, Y. Jia, J. Nishida, Z. Wang, K. D. Bunting, D. Wang, and H. Huang IL-3 Induces Basophil Expansion In Vivo by Directing Granulocyte-Monocyte Progenitors to Differentiate into Basophil Lineage-Restricted Progenitors in the Bone Marrow and by Increasing the Number of Basophil/Mast Cell Progenitors in the Spleen J. Immunol., March 1, 2009; 182(5): 2835 - 2841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zampetaki and Q. Xu Vascular Remodeling in Diabetes: Don't Leave Without Your STAT5 Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 10 - 11. [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. J. Wierenga, E. Vellenga, and J. J. Schuringa Maximal STAT5-Induced Proliferation and Self-Renewal at Intermediate STAT5 Activity Levels Mol. Cell. Biol., November 1, 2008; 28(21): 6668 - 6680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Kerenyi, F. Grebien, H. Gehart, M. Schifrer, M. Artaker, B. Kovacic, H. Beug, R. Moriggl, and E. W. Mullner Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1 Blood, November 1, 2008; 112(9): 3878 - 3888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Harir, C. Boudot, K. Friedbichler, K. Sonneck, R. Kondo, S. Martin-Lanneree, L. Kenner, M. Kerenyi, S. Yahiaoui, V. Gouilleux-Gruart, et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade Blood, September 15, 2008; 112(6): 2463 - 2473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Cohen, G. K. Koski, B. J. Czerniecki, K. D. Bunting, X.-Y. Fu, Z. Wang, W.-J. Zhang, C. S. Carter, M. Awad, C. A. Distel, et al. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells Blood, September 1, 2008; 112(5): 1832 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mina-Osorio, B. Winnicka, C. O'Conor, C. L. Grant, L. K. Vogel, D. Rodriguez-Pinto, K. V. Holmes, E. Ortega, and L. H. Shapiro CD13 is a novel mediator of monocytic/endothelial cell adhesion J. Leukoc. Biol., August 1, 2008; 84(2): 448 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kent, M. Copley, C. Benz, B. Dykstra, M. Bowie, and C. Eaves Regulation of Hematopoietic Stem Cells by the Steel Factor/KIT Signaling Pathway Clin. Cancer Res., April 1, 2008; 14(7): 1926 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schepers, D. van Gosliga, A. T. J. Wierenga, B. J. L. Eggen, J. J. Schuringa, and E. Vellenga STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells Blood, October 15, 2007; 110(8): 2880 - 2888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Dai, Y. Chen, L. Di, A. Podd, G. Li, K. D. Bunting, L. Hennighausen, R. Wen, and D. Wang Stat5 Is Essential for Early B Cell Development but Not for B Cell Maturation and Function J. Immunol., July 15, 2007; 179(2): 1068 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, E. Diaz-Flores, G. Li, Z. Wang, Z. Kang, E. Haviernikova, S. Rowe, C.-K. Qu, W. Tse, K. M. Shannon, et al. Abnormal hematopoiesis in Gab2 mutant mice Blood, July 1, 2007; 110(1): 116 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yao, Y. Kanno, M. Kerenyi, G. Stephens, L. Durant, W. T. Watford, A. Laurence, G. W. Robinson, E. M. Shevach, R. Moriggl, et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3 Blood, May 15, 2007; 109(10): 4368 - 4375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Van Etten Oncogenic signaling: new insights and controversies from chronic myeloid leukemia J. Exp. Med., March 19, 2007; 204(3): 461 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Ting, C.-W. Lin, S.-L. Wen, H.-M. Hsieh-Li, and H. Li Stat5 constitutive activation rescues defects in spinal muscular atrophy Hum. Mol. Genet., March 1, 2007; 16(5): 499 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Eckardt, N. A. Leu, H. L. Bradley, H. Kato, K. D. Bunting, and K. J. McLaughlin Hematopoietic reconstitution with androgenetic and gynogenetic stem cells Genes & Dev., February 15, 2007; 21(4): 409 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Harir, C. Pecquet, M. Kerenyi, K. Sonneck, B. Kovacic, R. Nyga, M. Brevet, I. Dhennin, V. Gouilleux-Gruart, H. Beug, et al. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias Blood, February 15, 2007; 109(4): 1678 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Panopoulos, L. Zhang, J. W. Snow, D. M. Jones, A. M. Smith, K. C. El Kasmi, F. Liu, M. A. Goldsmith, D. C. Link, P. J. Murray, et al. STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils Blood, December 1, 2006; 108(12): 3682 - 3690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Taylor, P. T. Walsh, D. F. LaRosa, J. Zhang, M. A. Burchill, M. A. Farrar, and L. A. Turka Constitutive Activation of STAT5 Supersedes the Requirement for Cytokine and TCR Engagement of CD4+ T Cells in Steady-State Homeostasis J. Immunol., August 15, 2006; 177(4): 2216 - 2223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chen, X. Dai, A. L. Haas, R. Wen, and D. Wang Proteasome-dependent down-regulation of activated Stat5A in the nucleus Blood, July 15, 2006; 108(2): 566 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hoelbl, B. Kovacic, M. A. Kerenyi, O. Simma, W. Warsch, Y. Cui, H. Beug, L. Hennighausen, R. Moriggl, and V. Sexl Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation Blood, June 15, 2006; 107(12): 4898 - 4906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ye, N. Wolff, L. Li, S. Zhang, and R. L. Ilaria Jr STAT5 signaling is required for the efficient induction and maintenance of CML in mice Blood, June 15, 2006; 107(12): 4917 - 4925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. J. Wierenga, H. Schepers, M. A. S. Moore, E. Vellenga, and J. J. Schuringa STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBP{alpha} Blood, June 1, 2006; 107(11): 4326 - 4333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yao, Y. Cui, W. T. Watford, J. H. Bream, K. Yamaoka, B. D. Hissong, D. Li, S. K. Durum, Q. Jiang, A. Bhandoola, et al. Stat5a/b are essential for normal lymphoid development and differentiation PNAS, January 24, 2006; 103(4): 1000 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Litherland, K. M. Grebe, N. S. Belkin, E. Paek, J. Elf, M. Atkinson, L. Morel, M. J. Clare-Salzler, and M. McDuffie Nonobese Diabetic Mouse Congenic Analysis Reveals Chromosome 11 Locus Contributing to Diabetes Susceptibility, Macrophage STAT5 Dysfunction, and Granulocyte-Macrophage Colony-Stimulating Factor Overproduction J. Immunol., October 1, 2005; 175(7): 4561 - 4565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kato, A. Iwama, Y. Tadokoro, K. Shimoda, M. Minoguchi, S. Akira, M. Tanaka, A. Miyajima, T. Kitamura, and H. Nakauchi Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis J. Exp. Med., July 5, 2005; 202(1): 169 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Couldrey, H. L. Bradley, and K. D. Bunting A STAT5 modifier locus on murine chromosome 7 modulates engraftment of hematopoietic stem cells during steady-state hematopoiesis Blood, February 15, 2005; 105(4): 1476 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cui, G. Riedlinger, K. Miyoshi, W. Tang, C. Li, C.-X. Deng, G. W. Robinson, and L. Hennighausen Inactivation of Stat5 in Mouse Mammary Epithelium during Pregnancy Reveals Distinct Functions in Cell Proliferation, Survival, and Differentiation Mol. Cell. Biol., September 15, 2004; 24(18): 8037 - 8047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Schuringa, K. Y. Chung, G. Morrone, and M. A.S. Moore Constitutive Activation of STAT5A Promotes Human Hematopoietic Stem Cell Self-Renewal and Erythroid Differentiation J. Exp. Med., September 7, 2004; 200(5): 623 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhu, L. Chen, Z. Huang, S. Alkan, K. D. Bunting, R. Wen, D. Wang, and H. Huang Cutting Edge: IL-5 Primes Th2 Cytokine-Producing Capacity in Eosinophils through a STAT5-Dependent Mechanism J. Immunol., September 1, 2004; 173(5): 2918 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kang, B. DiBenedetto, K. Narayan, H. Zhao, S. D. Der, and C. A. Chambers STAT5 Is Required for Thymopoiesis in a Development Stage-Specific Manner J. Immunol., August 15, 2004; 173(4): 2307 - 2314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Kollmann, S. S. Way, H. L. Harowicz, A. M. Hajjar, and C. B. Wilson Deficient MHC class I cross-presentation of soluble antigen by murine neonatal dendritic cells Blood, June 1, 2004; 103(11): 4240 - 4242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Bradley, C. Couldrey, and K. D. Bunting Hematopoietic-repopulating defects from STAT5-deficient bone marrow are not fully accounted for by loss of thrombopoietin responsiveness Blood, April 15, 2004; 103(8): 2965 - 2972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Sternberg and D. G. Gilliland The Role of Signal Transducer and Activator of Transcription Factors in Leukemogenesis J. Clin. Oncol., January 15, 2004; 22(2): 361 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Burchill, C. A. Goetz, M. Prlic, J. J. O'Neil, I. R. Harmon, S. J. Bensinger, L. A. Turka, P. Brennan, S. C. Jameson, and M. A. Farrar Distinct Effects of STAT5 Activation on CD4+ and CD8+ T Cell Homeostasis: Development of CD4+CD25+ Regulatory T Cells versus CD8+ Memory T Cells J. Immunol., December 1, 2003; 171(11): 5853 - 5864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Snow, N. Abraham, M. C. Ma, B. G. Herndier, A. W. Pastuszak, and M. A. Goldsmith Loss of Tolerance and Autoimmunity Affecting Multiple Organs in STAT5A/5B-Deficient Mice J. Immunol., November 15, 2003; 171(10): 5042 - 5050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Shelburne, M. E. McCoy, R. Piekorz, V. Sexl, K.-H. Roh, S. M. Jacobs-Helber, S. R. Gillespie, D. P. Bailey, P. Mirmonsef, M. N. Mann, et al. Stat5 expression is critical for mast cell development and survival Blood, August 15, 2003; 102(4): 1290 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Friedman, D. Nimbalkar, and F. W. Quelle Erythropoietin Receptors Associate with a Ubiquitin Ligase, p33RUL, and Require Its Activity for Erythropoietin-induced Proliferation J. Biol. Chem., July 11, 2003; 278(29): 26851 - 26861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gomez and N. C. Reich Stimulation of Primary Human Endothelial Cell Proliferation by IFN J. Immunol., June 1, 2003; 170(11): 5373 - 5381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Bradley, T. S. Hawley, and K. D. Bunting Cell intrinsic defects in cytokine responsiveness of STAT5-deficient hematopoietic stem cells Blood, December 1, 2002; 100(12): 3983 - 3989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ghilardi, J. Li, J.-A. Hongo, S. Yi, A. Gurney, and F. J. de Sauvage A Novel Type I Cytokine Receptor Is Expressed on Monocytes, Signals Proliferation, and Activates STAT-3 and STAT-5 J. Biol. Chem., May 3, 2002; 277(19): 16831 - 16836. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
/
